高级检索

老年非小细胞肺癌药物治疗进展

张泽柏

张泽柏. 老年非小细胞肺癌药物治疗进展[J]. 实用临床医药杂志, 2012, (19): 175-178.
引用本文: 张泽柏. 老年非小细胞肺癌药物治疗进展[J]. 实用临床医药杂志, 2012, (19): 175-178.
shu

老年非小细胞肺癌药物治疗进展

  • 广西壮族自治区龙潭医院肿瘤科,广西柳州,545005

基金项目: 中国高校医学期刊临床专项资金
详细信息

  • 中图分类号: R734.2

摘要

    摘要
  • 摘要: 老年恶性肿瘤中以肺癌的发病率及死亡率最高,而其中80％～85％为非小细胞肺癌(NSCLC).老年NSCLC患者基础代谢下降,身体机能出现严重衰退,且合并心脑血管及肺部多种基础疾病,导致其对手术、放疗及化疗的耐受性降低,治疗风险显著增加,这使得临床医师面对老年患者时,较难选择合适的治疗方案,从而延误病情,加速恶化.有研究认为[1],影响老年NSCLC患者预后的独立因素不是年龄,而是并发症,这一观点鼓励我们应在积极控制并发症、详细评估体能状态、保证器官功能良好的基础上,选择合适的化疗方案进行治疗,如此,老年患者甚至是高龄患者亦是可安全耐受化疗的.
    • HTML全文
    • 参考文献(32)
  • 杨萌, 林江涛. 老年人非小细胞肺癌的治疗进展 [J]. 中华老年医学杂志, 2008(6):476.
    Luciani A, Bertuzzi C, Ascione G. Dose intensity correlate with survival in elderly patients treated with chemotherapy for advanced non-small cell lung cancer [J]. Lung Cancer, 2009(1):94.
    Devlin JG, Langer CJ. Salvage therapy with vinorelbine in advanced non-small-cell lung cancer:a retrospective review of the Fox Chase Cancer Center experience and a review of the literature [J]. Clinical Lung Cancer, 2007(5):319.
    Rossi D, Catalano V, Alessandroni P. A phase Ⅱ study of single-agent oral vinorelbine in patients with pretreated advanced non-small-cell lung cancer [J]. Clinical Lung Cancer, 2007(6):382.
    Maione P, Rossi A, Sacco PC. Treating advanced non-small cell lung cancer in the elderly [J]. Ther Adv Med Oncol, 2010(4):251.
    Toschi L, Cappuzzo F. Gemcitabine for the treatment of advanced nonsmall cell lung cancer [J]. Onco Targets Ther, 2009.209.
    方立萍, 吴紫权, 乔京京. 吉西他滨单药治疗老年晚期非小细胞肺癌46例 [J]. 肿瘤学杂志, 2010(5):411.
    赵银利, 谭焕明. 吉西他滨单药治疗老年晚期非小细胞肺癌的临床观察 [J]. 临床肿瘤学杂志, 2008(5):458.doi: 10.3969/j.issn.1009-0460.2008.05.019.
    劳逸, 陈绍峰, 蔡永广. 吉西他滨单药或联合顺铂治疗高龄晚期非小细胞肺癌临床研究 [J]. 肿瘤基础与临床, 2007(6):1170.
    Rossi D, Dennetta D, Ugolini M. Weekly paclitaxel in elderly patients (aged 》 or =70 years) with advanced non-small cell lung cancer:an alternative choice. Results of a phase Ⅱ study [J]. Clinical Lung Cancer, 2008(5):280.
    Karampeazis A, Vamvakas L, Agelidou A. Docetaxel vs.vinorelbine in elderly patients with advanced non-small cell lung cancer:a hellenic oncology research group randomized phase Ⅲ study [J]. Clinical Lung Cancer, 2011(3):155.
    Hainsworth J D, Spigel D R, Farley C. Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer:a randomized phase 3 trial of the Minnie Pearl Cancer Research Network [J]. Cancer, 2007(9):2027.
    王英. 多西他赛单药每周与三周疗法治疗老年晚期非小细胞肺癌的对比观察 [J]. 中华肿瘤防治杂志, 2010, (16):1311.
    Otani S, Igawa S, Maki S. Pemetrexed as second-line treatment and beyond for elderly patients with advanced non-small cell lung cancer [J]. Gan to Kagaku Ryoho(Japanese Journal of Cancer and Chemotherapy), 2012(1):59.
    Vergnenegre A, Corre R, Berard H. Cost-effectiveness of second-line chemotherapy for non-small cell lung cancer:an economic, randomized, prospective, multicenter phase Ⅲ trial comparing docetaxel and pemetrexed:the GFPC 05-06 study [J]. JOURNAL OF THORACIC ONCOLOGY, 2011(1):161.
    Kim D Y, Lee D H, Jang S J. Phase Ⅱ Study of S-1 Plus Either Irinotecan or Docetaxel for Non-small Cell Lung Cancer Patients Treated with More Than Three Lines of Treatment [J]. Cancer Res Treat, 2011(4):212.
    于飞, 刘晓晴, 李晓燕. 培美曲塞单药或联合铂类三线及以上治疗晚期非鳞型非小细胞肺癌的临床观察 [J]. 中国肺癌杂志, 2012(2):117.doi: 10.3779/j.issn.1009-3419.2012.02.10.
    Kawamura M, Eguchi K, Izumi Y. Phase Ⅱ trial of gemcitabine and docetaxel in patients with completely resected stage IIA-IIIA non-small-cell lung cancer [J]. Cancer Chemotherapy and Pharmacology, 2007(4):495.
    Huebner G, Link H, Kohne C H. Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno-or undifferentiated carcinoma of unknown primary:a randomised prospective phase Ⅱ trial [J]. British Journal of Cancer, 2009(1):44.
    Russo A, Rizzo S, Fulfaro F. Gemcitabine-based doublets versus single-agent therapy for elderly patients with advanced nonsmall cell lung cancer:a Literature-based Metaanalysis [J]. Cancer, 2009(9):1924.
    LeCaer H, Fournel P, Jullian H. An open multicenter phase Ⅱ trial of docetaxel-gemcitabine in Charlson score and performance status (PS) selected elderly patients with stage Ⅲ B pleura/Ⅳ non-small-cell lung cancer (NSCLC):the GF-PC 02-02a study [J]. Critical Reviews in Oncology/Hematology, 2007(1):73.
    Daga H, Takeda K, Kiyota H. Is the platinum-based chemotherapy necessary for elderly patients with advanced Non-small Cell Lung Cancer (NSCLC) [J]. Journal of Clinical Oncology, 2008.a19088.
    Sakakibara T, Inoue A, Sugawara S. Randomized phase Ⅱ trial of weekly paclitaxel combined with carboplatin versus standard paclitaxel combined with carboplatin for elderly patients with advanced non-small-cell lung cancer [J]. Annals of Oncology, 2010(4):795.
    Biesma B, Wymenga A N, Vincent A. Quality of life, geriatric assessment and survival in elderly patients with non-small-cell lung cancer treated with carboplatin-gemcitabine or carboplatin-paclitaxel:NVALT-3 a phase Ⅲ study [J]. Annals of Oncology, 2011(7):1520.
    曾晓梅, 李之曦, 侯梅. 紫杉醇脂质体单药与紫杉醇脂质体联合奥沙利铂一线治疗老年晚期非小细胞肺癌的随机对照研究 [J]. 中国肺癌杂志, 2012(2):84.doi: 10.3779/j.issn.1009-3419.2012.02.04.
    Kobayashi M, Matsui K, Katakami N. Phase Ⅱ study of gefitinib as a first-line therapy in elderly patients with pulmonary adcnocarcinoma:West Japan Thoracic Oncology Group Study 0402 [J]. Japanese Journal of Clinical Oncology, 2011(8):948.
    Kim S T, Uhm J E, Lee J. Randomized phase Ⅱ study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy [J]. Lung Cancer, 2012(1):82.
    Leighl N B, Zatloukal P, Mezger J. Efficacy and safety of bevacizumab-based therapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer in the phase Ⅲ BO17704 study (AVAiL) [J]. JOURNAL OF THORACIC ONCOLOGY, 2010, (12):1970.
    Mok T S, Hsia T C, Tsai C M. Efficacy of bevacizumab with cisplatin and gemcitabine in Asian patients with advanced or recurrent non-squamous non-small cell lung cancer who have not received prior chemotherapy:a substudy of the Avastin in Lung trial [J]. Asia Pac J Clin Oncol, 2011, (Suppl 2):4.
    Niho S, Kunitoh H, Nokihara H. Randomized phase Ⅱ study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer [J]. Lung Cancer, 2012(3):362.
    方红明, 余新民, 施勋. 多西他赛联合重组人血管内皮抑制素治疗老年晚期非小细胞肺癌的临床观察 [J]. 中华肿瘤防治杂志, 2010, (18):1460.
    陈群, 石琴, 谢强. 重组人血管内皮抑素注射液联合单药治疗老年晚期非小细胞肺癌的临床观察 [J]. 中国老年学杂志, 2012(5):900.doi: 10.3969/j.issn.1005-9202.2012.05.006.
    • 相关文章
    • 施引文献
    • 资源附件(0)
计量
  • 文章访问数: 
  • HTML全文浏览量: 
  • PDF下载量: 
  • 被引次数: 0
出版历程
  • 发布日期:  2013-01-15

目录

摘要
HTML全文
    参考文献(32)
    相关文章
    施引文献
    资源附件(0)

    /

    返回文章
    返回

    © 2020 《实用临床医药杂志》编辑部

    地址：江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室邮编：225009电话：0514-87978917、87978989、87978807

    苏公网安备 32100302010246号

    本系统由 北京仁和汇智信息技术有限公司 开发  百度统计